Birdwatch Note
2023-03-06 02:51:56 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Hydroxychloroquine and ivermectin have shown no efficacy for COVID-19 based on randomized controlled trials. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/full https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362 https://jamanetwork.com/journals/jama/fullarticle/2777389 https://www.sciencedirect.com/science/article/pii/S1477893921001769
Written by 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1632570679739514880
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1632574706434834432
- noteId - 1632574706434834432
- participantId - 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31
- noteAuthorParticipantId -
- createdAtMillis - 1678071116441
- tweetId - 1632570679739514880
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Hydroxychloroquine and ivermectin have shown no efficacy for COVID-19 based on randomized controlled trials. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/full https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362 https://jamanetwork.com/journals/jama/fullarticle/2777389 https://www.sciencedirect.com/science/article/pii/S1477893921001769
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-03-06 02:51:56 UTC (1678071116441) |
1969-12-31 23:59:59 UTC (-1) |
2023-03-07 02:11:29 UTC (1678155089929) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-03-06 08:06:15 -0600 | 1365531EFAB217578BF371EFEDF299481BDB4590E6D9CCEFF9AA569DBAC265A4 | Rating Details |
2023-03-06 17:46:58 -0600 | 13CFEBB121BCDB4F34A72B049594DDE1184A31F965F4BB82E5492600140A1E1E | Rating Details |
2023-03-05 21:34:05 -0600 | 15AC981BB524E289C4BADA3E120317CEFA588E9367F8349C5CB3EFA54A4AD864 | Rating Details |
2023-03-05 21:32:02 -0600 | 18EBFED4BABEF4717E4E03C64045A565C0791B6E511884BF88740424F9037AC8 | Rating Details |
2023-03-06 08:46:49 -0600 | 1E821F94A8083744BD40525662B0A6E9D301390FB82A16218CFD2D52F1C09ABC | Rating Details |
2023-03-09 22:23:05 -0600 | 2A836FABCCF0EE6EDFD7AD9F50AC054C030FCB9D215F09D984494EDBB10BF074 | Rating Details |
2023-03-06 08:26:21 -0600 | 34BC1E89C4723C2FD1C55D5F18AA5914BF41C2C20256EDDC887AAF53C41280D7 | Rating Details |
2023-03-05 21:53:52 -0600 | 45060ED935D102E05C21C743FE433C0B17B27D8FCF69CED01A2AD3F9AB2815B1 | Rating Details |
2023-03-06 07:35:19 -0600 | 45B8EF43682258D990F1C39DD9C1C131E030B7B116A1A874CAD37AED55F98C04 | Rating Details |
2023-03-06 01:05:40 -0600 | 46CA5AE021772DE44A2359478C64A1F94A7515784CAA8092D14C8638E7B30DD5 | Rating Details |
2023-03-06 17:09:09 -0600 | 4CFF19BD69F823E18A5AFBF5CD7648436BD1D8B0C02EBB4B6789AA19064063E0 | Rating Details |
2023-03-06 10:01:44 -0600 | 4DF1CDFBEA3F6DE525FEEC58EEAF593D6DE2475010A316ED6876FA4CA230339A | Rating Details |
2023-03-06 07:55:57 -0600 | 62ED08CF2EC5B7F0F80869A6D55C59FE79D6011AB28A81D041B0D2F771BA4670 | Rating Details |
2023-03-06 03:18:53 -0600 | 70C41EBA84E24EF79E6580BE4D20ED5A38DFDE5397010F1ED4197E9DE3FDF5FE | Rating Details |
2023-03-06 03:12:21 -0600 | 71A8D089BB7143D7CFA04A0D7EEF5C32B3B2901386875FDE172BA7A711F2ADB9 | Rating Details |
2023-03-05 21:33:11 -0600 | 71EB268E7A8F69DFC819CAAE0A760DFD1B895A145E18F142043E0C9900DB4061 | Rating Details |
2023-03-05 21:23:02 -0600 | 725FD1C62D6AAB73D85C1B4D5C3655FA529B18AD3D3977B24A0921FED3EB0C9C | Rating Details |
2023-03-06 00:32:07 -0600 | 74E58FA83744E524658ABCA5B13A0585DD2944D50E4BE0301C4A81EAA689B71E | Rating Details |
2023-03-06 00:26:22 -0600 | 75F32FEA46988AB3A0D35FABE92BF99E44C13500576278BD2F9F5998A7778FF8 | Rating Details |
2023-03-06 07:40:45 -0600 | 767A25099EA0897CBDF690092195163EEB1A81438144281406526375119992F3 | Rating Details |
2023-03-06 00:46:49 -0600 | 7981A2C40D6150AF302C8AD7A987AA43203E1B7AD414C9BDAD30EB7DC45672CB | Rating Details |
2023-03-07 13:03:41 -0600 | 7B21754FD69D11EC635B7D0F5C8BB9199F9932702310DB6A5D1ABD92B4FF9462 | Rating Details |
2023-03-06 08:58:15 -0600 | 7C318A55DA967AF307404F852FA3E254598BEE744D950C842E03E0C6CD019D14 | Rating Details |
2023-03-05 21:39:44 -0600 | 83F8C9FBF04EDF7CE0402610D70596E31ACF4323833A5EAB7FFC83BF5104A1FC | Rating Details |
2023-03-05 21:18:53 -0600 | 85D9ED07A0859616694BB1F5D2FF9F3B4352FBAA0FF0340518C7512D999BC872 | Rating Details |
2023-03-06 00:45:34 -0600 | 939F206BD22CA127236406BD15593556984D51C6E976A9311C96F74FE47FD05D | Rating Details |
2023-03-06 02:25:49 -0600 | 94D6F49DC83AD218D6D405C9224306ADA3B6AE0FF56571D96CB7C9E4156C9208 | Rating Details |
2023-03-06 01:24:46 -0600 | 9B0F92587FEA7E705E5075FF71040543E7DD9C5021924EE7CAF31CA39F9939B9 | Rating Details |
2023-03-06 08:05:03 -0600 | 9E2542433FE055CBA699C5BEFB0B26A4264D7132E4490E602FBE123D2E5015F2 | Rating Details |
2023-03-06 05:15:56 -0600 | A2A448D9C14B2F0C078E3904605B560F051F89FE9F8F6FBEC3B885792ED95084 | Rating Details |
2023-03-06 01:22:21 -0600 | A30E23B01F927C4387616E33DE422C96B4F9A9B45B8ACA619267391F3D77B5A8 | Rating Details |
2023-03-07 00:01:30 -0600 | AC3178096A6F592734EFC82ACE2CDFFFE26BAFF6BC8FEA38C34D87F12E3A712E | Rating Details |
2023-03-06 04:45:22 -0600 | AD8DC42A0C7729F56C4F30E56E6262C5285C3CADAB680599CAF1924DEA605484 | Rating Details |
2023-03-05 21:06:24 -0600 | B5FEE1C7F02671E2466AE0184315222BE9F827034DA0D608839BE86F8B7D554A | Rating Details |
2023-03-06 08:16:57 -0600 | C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3 | Rating Details |
2023-03-06 02:12:21 -0600 | C966E0BA5803EDA2B9ADEA1A226B5D5FB13629349A2D9A920F01C5137F8AF13B | Rating Details |
2023-03-05 21:10:01 -0600 | CAB67BCDBD84E1DD6FCCDFF9A860DC17934BDC829264B174FBC2C36F79B1D4B1 | Rating Details |
2023-03-06 08:39:18 -0600 | CC5EEE308BFD8D0C2B11CC363A5390BAAE07C877B1CB438B9BC6C00E57237273 | Rating Details |
2023-03-06 00:59:57 -0600 | CE2DE647C2D2D1EE3738900B91EB4094D8F06FEA3FCF4D00EFC4D49B276FEC24 | Rating Details |
2023-03-06 12:55:23 -0600 | DC1B038605EB7B153771BACDFFE6C9D25363704191B3240E4AAC28B7E18C77A6 | Rating Details |
2023-03-05 21:01:27 -0600 | E2605BEAD46C27CF8FA369A04ED5D42F0CFF4C57A0409AB3D8F61C8BDE536DA5 | Rating Details |
2023-03-05 21:52:55 -0600 | EB8B9EEDF326893E3FD57C82A33F0743B629690EF66527137B4719B0AB1796FA | Rating Details |
2023-03-05 21:27:20 -0600 | EE848598DCEB775E05753C8F9E2E1AE83D325CB4435FD8358DDAE49CFFA026ED | Rating Details |
2023-03-06 02:28:35 -0600 | F7E1BEEDF9E902801B5DA5B285FEDC143B273DD031F0B76CE601E81482F0C2EB | Rating Details |
2023-03-06 14:01:03 -0600 | FD356740B9A4AC56B200AC568AE260DC4A1C21FF5AF2C4F6E3D6D71B8BDC947E | Rating Details |
2023-03-07 20:22:10 -0600 | FD89EFB54BF22A6038EFA17EB32EA5B7D16091743F333AEDBD3DCD657161FDC2 | Rating Details |
2023-03-06 02:12:21 -0600 | Rating Details | |
2023-03-06 17:46:58 -0600 | Rating Details | |
2023-03-06 00:32:07 -0600 | Rating Details | |
2023-03-06 07:35:19 -0600 | Rating Details | |
2023-03-06 03:12:21 -0600 | Rating Details | |
2023-03-07 20:22:10 -0600 | Rating Details | |
2023-03-06 08:46:49 -0600 | Rating Details | |
2023-03-06 14:01:03 -0600 | Rating Details | |
2023-03-06 02:28:35 -0600 | Rating Details | |
2023-03-06 00:46:49 -0600 | Rating Details | |
2023-03-06 08:05:03 -0600 | Rating Details | |
2023-03-05 21:18:53 -0600 | Rating Details | |
2023-03-05 21:06:24 -0600 | Rating Details | |
2023-03-06 08:16:57 -0600 | Rating Details | |
2023-03-05 21:53:52 -0600 | Rating Details | |
2023-03-07 13:03:41 -0600 | Rating Details | |
2023-03-05 21:34:05 -0600 | Rating Details | |
2023-03-06 08:26:21 -0600 | Rating Details | |
2023-03-06 07:55:57 -0600 | Rating Details | |
2023-03-05 21:27:20 -0600 | Rating Details | |
2023-03-06 08:39:18 -0600 | Rating Details | |
2023-03-05 21:39:44 -0600 | Rating Details | |
2023-03-05 21:23:02 -0600 | Rating Details | |
2023-03-06 04:45:22 -0600 | Rating Details | |
2023-03-06 01:22:21 -0600 | Rating Details | |
2023-03-07 00:01:30 -0600 | Rating Details | |
2023-03-06 05:15:56 -0600 | Rating Details | |
2023-03-05 21:32:02 -0600 | Rating Details | |
2023-03-06 01:24:46 -0600 | Rating Details | |
2023-03-06 07:40:45 -0600 | Rating Details | |
2023-03-06 00:45:34 -0600 | Rating Details | |
2023-03-05 21:10:01 -0600 | Rating Details | |
2023-03-06 08:58:15 -0600 | Rating Details | |
2023-03-06 08:06:15 -0600 | Rating Details | |
2023-03-06 01:05:40 -0600 | Rating Details | |
2023-03-06 02:25:49 -0600 | Rating Details | |
2023-03-06 10:01:44 -0600 | Rating Details | |
2023-03-05 21:01:27 -0600 | Rating Details | |
2023-03-05 21:52:55 -0600 | Rating Details | |
2023-03-06 17:09:09 -0600 | Rating Details | |
2023-03-09 22:23:05 -0600 | Rating Details | |
2023-03-06 12:55:23 -0600 | Rating Details | |
2023-03-06 03:18:53 -0600 | Rating Details | |
2023-03-06 00:59:57 -0600 | Rating Details |